Veloxis Pharmaceuticals
CompanyUnited States
Veloxis Pharmaceuticals develops one asset, approved (tacrolimus in Dermatitis, Atopic). Mostly small molecule acting on inflammation, FKBP1A and PPP3CA; based in the United States.
- 1
- Asset
- Furthest
- Approved
- 13
- Trials
- 0
- Signals
Pipeline
1Binds FKBP12 to inhibit calcineurin, suppressing T-cell activation and inflammatory cytokine production.
Approved, Small molecule, Inflammation, FKBP1A, Dermatitis, Atopic, graft rejection
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials32
- Signals1
- Similar companies6
Updated 12 Oct 2026 · 61 sources